StockData
Alnylam Pharmaceuticals, Inc. logo

Alnylam Pharmaceuticals, Inc. (ALNY) stock

ALNYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 10/3047% below fair value
$156.50−3.23 (-2.02%)

Close on Nov 17, 2026Market cap $20.96BP/E 8.1Yield –

Alnylam Pharmaceuticals operating margin

Operating margin is operating income as a percentage of revenue.

Alnylam Pharmaceuticals's operating margin for the twelve months ending Sep 30, 2026 was 19.5%. For fiscal 2025 it was 13.5%, against -7.9% the year before. The highest annual figure on record is 13.5% in fiscal 2025.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202513.5%+21.4
FY2024Dec 31, 2024-7.9%+7.6
FY2023Dec 31, 2023-15.4%+60.2
FY2022Dec 31, 2022-75.7%+8.3
FY2021Dec 31, 2021-83.9%+84.2
FY2020Dec 31, 2020-168.1%+259.4
FY2019Dec 31, 2019-427.5%+660.1
FY2018Dec 31, 2018-1087.6%−531.4
FY2017Dec 31, 2017-556.2%+344.1
FY2016Dec 31, 2016-900.3%−856.3
FY2010Dec 31, 2010-44.1%+3.8
FY2009Dec 31, 2009-47.9%−18.9
FY2008Dec 31, 2008-28.9%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q3 FY2026Sep 30, 202623.7%−5.7
Q2 FY2026Jun 30, 202617.9%+20.0
Q1 FY2026Mar 31, 202623.0%+20.0
Q4 FY2025Dec 31, 202512.0%+29.7
Q3 FY2025Sep 30, 202529.5%+44.8
Q2 FY2025Jun 30, 2025-2.1%−9.5
Q1 FY2025Mar 31, 20253.0%+11.8
Q4 FY2024Dec 31, 2024-17.7%+8.7
Q3 FY2024Sep 30, 2024-15.4%−43.8
Q2 FY2024Jun 30, 20247.4%+79.5
Q1 FY2024Mar 31, 2024-8.8%+38.1
Q4 FY2023Dec 31, 2023-26.5%+29.8
Q3 FY2023Sep 30, 202328.5%+126.1
Q2 FY2023Jun 30, 2023-72.1%+13.2
Q1 FY2023Mar 31, 2023-46.9%+21.9
Q4 FY2022Dec 31, 2022-56.3%+19.0
Q3 FY2022Sep 30, 2022-97.6%−0.8
Q2 FY2022Jun 30, 2022-85.3%−19.0
Q1 FY2022Mar 31, 2022-68.8%+36.1
Q4 FY2021Dec 31, 2021-75.3%+43.5
Q3 FY2021Sep 30, 2021-96.8%+82.1
Q2 FY2021Jun 30, 2021-66.3%+125.0
Q1 FY2021Mar 31, 2021-104.9%+106.4
Q4 FY2020Dec 31, 2020-118.7%+297.1
Q3 FY2020Sep 30, 2020-178.9%+129.8
Q2 FY2020Jun 30, 2020-191.3%+337.1
Q1 FY2020Mar 31, 2020-211.3%+355.8
Q4 FY2019Dec 31, 2019-415.8%+631.8
Q3 FY2019Sep 30, 2019-308.7%+11994.7
Q2 FY2019Jun 30, 2019-528.4%+114.8
Q1 FY2019Mar 31, 2019-567.0%+106.1
Q4 FY2018Dec 31, 2018-1047.7%−659.3
Q3 FY2018Sep 30, 2018-12303.4%−11567.6
Q2 FY2018Jun 30, 2018-643.2%+113.0
Q1 FY2018Mar 31, 2018-673.1%−111.3
Q4 FY2017Dec 31, 2017-388.4%–
Q3 FY2017Sep 30, 2017-735.8%–
Q2 FY2017Jun 30, 2017-756.2%–
Q1 FY2017Mar 31, 2017-561.8%–

More Alnylam Pharmaceuticals figures

See a number that looks wrong?